Why Are FIIs Raising Their Stake in This Pet Pharma Company?
Synopsis: In the June 2026 quarter, the company demonstrated strong financial momentum, driven by significant EBITDA margin expansion and a strategic transition from a pure API manufacturer to a formulations-led business. .
The animal health business, which most investors still refer to as SeQuent Scientific, has been discreetly re-establishing itself. Foreign institutional investors increased their stake from 2.94% at the end of March to 4.50%, an increase of about 156 basis points in just one quarter. This scale of institutional buying interest calls for a closer examination of the underlying changes.
Shares of Viyash Scientific closed on Monday around Rs. 252.15, down 1.37 percent from its previous close of Rs.255.65, giving it a market capitalisation of approximately Rs. 10,987.42 crore. The stock trades at a P/E of 52.24x.
A Platform, Not Just an API Company
With a portfolio of more than 90 APIs, more than 30 human health products, and more than 140 animal health products, supported by more than 250 scientists and more than 1,000 registrations in more than 150 countries, Viyash now positions itself as an integrated pharmaceutical platform covering human health, animal health, and CDMO.
This positioning is significant because it represents a change from the company’s more limited animal-health identity under its previous SeQuent branding. The Q1 FY27 numbers support this change with actual revenue mix data rather than just messaging.
Formulations, Not APIs, Are Now the Growth Engine
Formulations revenue increased 33% year over year to Rs. 555 crore in Q1 FY27, while APIs revenue increased only 4% to Rs. 383 crore. As a result, the faster-growing portion of the business is no longer the conventional API engine that defined the company in the past. This reversal in growth leadership between segments is the quarter’s most significant structural signal.
Additionally, formulation growth was not concentrated in a single market; sales increased by 63% in India, 60% in the US, 36% in emerging markets, and 13% in Europe. This gave the company a broader growth base than would be possible with a single-market or single-segment story, and it decreased the possibility that a slowdown in any one region would impede overall growth.
Margin Expansion Is Outrunning Revenue Growth
Although Q1 FY27 revenue rose 19.5% year over year to Rs. 946 crore, adjusted EBITDA increased 59.2% to Rs. 205 crore, increasing EBITDA margin by 540 basis points from 16.2% to 21.6%. Earnings before tax increased 132.8% year over year to Rs. 112.4 crore, while earnings after tax increased 114.9% to Rs. 79.3 crore.
A portion of this can be explained by two disclosed items: finance costs decreased as net debt was reduced, a real and ongoing benefit, while ESOP costs increased as a result of incremental grants linked to the amalgamation scheme, a real but non-cash drag.
Net debt decreased to Rs. 86.1 crore from Rs. 166.1 crore, and net debt to LTM EBITDA improved to 0.1x from 0.2x in the previous quarter, suggesting the balance sheet is being actively delevered even as the company concurrently funds acquisitions.
R&D Depth Behind the Formulations Push
The expansion of formulations is not occurring independently of R&D capacity. Viyash employs more than 225 people in API R&D, more than 60 in human formulation R&D, and more than 55 in animal health R&D. The API R&D department is particularly focused on complex molecules, such as cytotoxic APIs and high-potent OEB 4/5.
This focus on complexity is important because, in line with the company’s reported margin expansion, complex, more difficult-to-replicate molecules usually have more pricing power and fewer competitors than commodity API lines.
What Should Investors Look Out For
Since part of the FII stake increase may be related to Carlyle’s stake sale rather than new institutional conviction, it is better to watch what happens next rather than treating it as a stand-alone bullish signal. Future quarters will show whether FIIs are still adding or have just absorbed a one-time placement.
The Bio For Life acquisition in Italy, whose SPA was completed on July 21, 2026, and its closing is anticipated in September 2026, is completely outside the scope of this quarter’s figures. As a result, its financial contribution and the viability of the companion-animal thesis behind it are still unknown.
Lastly, the stock’s valuation already accounts for a significant portion of the margin story at a market capitalisation of about Rs. 10,987.42 crore against a still-developing formulations base, leaving less space for execution slippage on the Bio For Life integration or additional ESOP-related cost surprises.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
